Home
AltheaDx

AltheaDx Market Share Analysis for November 2025

at idgenetix, pgx testing helps physicians find the best medication for their patients, without bad side effects. try pgx testing today!

Health > Biotechnology and Pharmaceuticals

Domainaltheadx.com

Year Founded2009

Employees51 - 200

Annual Revenue$15M - $25M

AltheaDx

AltheaDx (including company regionals)

altheadx.com

See more website traffic and engagement information

AltheaDx Revenue up to November 2025 is 15M - 25M

revenue generated by AltheaDx top domains

AltheaDx top domains revenue over 3 years

Revenue for AltheaDx top domains

altheadx.com15M - 25M

See more with Sales Intelligence

Total visits to AltheaDx's top domains

Understand AltheaDx market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in AltheaDx's top domains

Analyze AltheaDx engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on AltheaDx's top domains

See how AltheaDx keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

AltheaDx top competitors by domain

Top similar sites in November 2025, ranked by their affinity

rarecyte.comCompany NameRareCyteEmployees51 - 200HQUnited States, Washington, SeattleAnnual revenue$2M - $5MTotal visits2.5KHealth > Biotechnology and Pharmaceuticals

Top technologies used by AltheaDx

These are the website technologies, by industry, used by AltheaDx top domains

Widget (5)

Twemoji

Content Management System (3)

WordPress

Advertising (2)

DoubleClick

Marketing (2)

Google Marketing Platform

More Technologies

6

See all

News & Signals from AltheaDx

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCastle Biosciences, Inc. acquired Altheadx for $140M on Apr 4th '22.Castle Biosciences acquired AltheaDx for initial consideration of $65 million, consisting of $32.5 million in cash, subject to adjustments for cash, debt, expenses and working capital, and $32.5 million in common stock of Castle Biosciences.

NewsAltheadx hired Jonathan Yount as SVP of Sales on Aug 18th '21.AltheaDx, a commercial stage, precision medicine company with a leading pharmacogenomics (PGx) test for anxiety and depression, announced today the expansion of its commercial leadership team with the appointment of Jonathan Yount, SVP of Sales.

NewsAltheadx launches series of webinars.AltheaDx, a commercial stage precision medicine company with a leading pharmacogenomics test (PGx) for depression and anxiety, has launched a series of webinars.